Altria Group (MO) — Q2 2026 Earnings Preview
Key Points
| Factor | Details |
|---|---|
| Guidance | Reaffirmed FY26 adjusted diluted EPS guidance: $5.56–$5.72 (+2.5% to +5.5% YoY) |
| Consensus Q2 2026 EPS | $1.49 (GAAP, consensus) |
| Consensus Q2 2026 Revenue | $5,351M (rounded, consensus) |
| Q1 2026 Actuals | Revenue $5,428M (+3.2% YoY), Adj. EPS $1.32 (+7.3% YoY) |
| Q2 2025 Actuals | Revenue $5,189M, Adj. EPS $1.44 |
| Y/Y Comparable | Q2 2025 was a strong quarter with 8.3% adj. EPS growth; Q2 2026 faces a tough comp |
| Most Important Factors |
|
Summary and Conclusions
- Altria enters Q2 2026 coming off a strong Q1, with adjusted EPS up 7.3% YoY and reaffirmed full-year guidance.
- Q2 2026 faces a tough comparable: Q2 2025 saw robust adjusted EPS growth (+8.3%) and solid smokeable segment performance.
- Consensus expects Q2 2026 revenue of $5,351M and GAAP EPS of $1.49. Management’s guidance implies a more balanced EPS growth split between H1 and H2, after initially expecting a back-half weighting.
- Key focus areas for the print: Progress on import/export activity and duty drawback benefits, resilience of smokeable volumes (especially discount share gains), margin trends in both smokeable and oral segments, and the national rollout of on! PLUS.
- Macro headwinds remain: Management continues to flag consumer pressure from inflation and gas prices, which is driving discount segment growth and impacting Marlboro share.
- Regulatory environment: Watch for commentary on FDA enforcement against illicit e-vapor, PMTA progress for new pouch flavors, and any update on NJOY ACE or e-vapor pipeline.
Forward-Looking Consensus and Guidance
FY2026 Guidance (as of Q1 2026)
| Metric | Guidance (FY2026) | Notes |
|---|---|---|
| Adjusted Diluted EPS | $5.56–$5.72 | +2.5% to +5.5% YoY from $5.42 base (FY2025) |
| Adjusted Effective Tax Rate | 22.5%–23.5% | |
| Capital Expenditures | $300M–$375M | Includes investments for import/export and innovative products |
| Depreciation & Amortization | ~$225M |
Guidance Commentary- Management expects EPS growth to be more balanced between H1 and H2, reflecting stronger Q1 and Q2 performance than initially anticipated.
- Guidance contemplates: progressive increase in cigarette import/export activity, planned investments in contract manufacturing, no return of NJOY ACE in 2026, reinvestment of cost savings from Optimize & Accelerate, and continued macro uncertainty.
- Guidance excludes impacts from special items (e.g., asset impairments, litigation, acquisition/disposition, certain tax items).
Consensus Estimates (Q2 2026 and FY2026)
Quarterly (Q2 2026)
| Metric | Consensus Estimate | Q2 2025 Actual | YoY Change (Consensus) |
|---|---|---|---|
| Revenue ($M) | $5,351 | $5,189 | +3.1% |
| GAAP EPS | $1.49 | $1.37* | +8.8% |
*Q2 2025 GAAP EPS per consensus: $1.37; Company reported $1.41 (press release).
Annual (FY2026)
| Metric | Consensus Estimate | FY2025 Actual | YoY Change (Consensus) |
|---|---|---|---|
| Revenue ($M) | $20,535 | $20,108 | +2.1% |
| GAAP EPS | $5.59 | $4.87 | +14.8% |
Q2 2025 Actuals (Restated Where Applicable)
| Metric | Q2 2025 Actual (Company Reported) |
|---|---|
| Revenue ($M) | $5,189 |
| Adj. Diluted EPS | $1.44 |
| GAAP EPS | $1.41 |
| Adj. EPS Growth | +8.3% YoY |
| Net Income ($M) | $2,349 (consensus), $2,378 (company) |
| Gross Margin | 76.8% (consensus) |
- Q2 2025 was a strong quarter: Adj. EPS +8.3% YoY, driven by higher adjusted OCI and fewer shares outstanding.
- Smokeable segment: Adjusted OCI +4.2% YoY, margin expansion to 64.5%.
- Oral tobacco segment: Adjusted OCI +10.9% YoY, margin expansion to 68.7%.
- Discount segment: Notable retail share gains, reflecting consumer trade-down.
What to Watch for in Q2 2026
1. EPS Delivery vs. Guidance and Consensus- Is Altria tracking toward the upper or lower end of its $5.56–$5.72 FY26 EPS range?
- Does Q2 EPS beat or miss the $1.49 consensus?
2. Smokeable Volume and Mix- Are cigarette volumes continuing to moderate in their rate of decline? Q1 2026 saw a reported -2.4% YoY decline (vs. -10.2% in Q2 2025).
- How much of the volume is driven by discount brands (Basic), and is Marlboro holding share in the premium segment?
3. Discount Segment Dynamics- Discount retail share grew +2.4 pts YoY in Q1 2026; Basic captured all of this gain.
- Is the discount segment still expanding, or is it plateauing as Basic annualizes its repositioning?
4. Oral Tobacco and on! PLUS Rollout- National launch of on! PLUS began in March 2026; is there evidence of early consumer offtake and incremental share?
- Are oral tobacco margins holding up amid higher promo spend and mix shift to pouches?
5. Duty Drawback/Import-Export Benefit- Q1 2026 saw the first meaningful benefit from cigarette export activity and duty drawback.
- Is the benefit ramping as expected through Q2 and into H2, and how much is dropping through to OCI?
6. Macro Headwinds and Consumer Health- Management continues to flag inflation and gas prices as headwinds for price-sensitive consumers.
- Are there signs of further trade-down, or is the consumer stabilizing?
7. Regulatory and Enforcement Updates- Any update on FDA enforcement against illicit e-vapor, PMTA progress for new pouch flavors, or NJOY ACE/e-vapor pipeline timing?
- Is the regulatory environment improving for legal smoke-free products?
